Quantumzyme Patents Enable Sustainable Ibuprofen Production Through Enzyme Engineering

Quantumzyme Corp. has announced details regarding the World Intellectual Property Organization publication of its international patent application titled "Modified Polypeptides for Enzymatic Synthesis of Ibuprofen" (Publication No. WO 2025/093935 A1). The company is highlighting this publication to demonstrate its ongoing progress and commitment to innovation in sustainable pharmaceutical manufacturing, reflecting a broader growth strategy focused on expanding enzyme engineering capabilities and strengthening intellectual property protection.

The patent publication follows the company's earlier announcement of its U.S. Patent Application Publication No. US 2025/0146029 A1 covering related enzymatic processes. Together, these filings establish comprehensive protection for Quantumzyme's proprietary enzyme engineering platform across both United States and international markets. These developments represent a major step toward commercializing an enzymatic process for sustainable ibuprofen manufacturing that reduces chemical waste, eliminates harsh reagents, and enhances overall manufacturing efficiency.

Naveen Kulkarni, CEO of Quantumzyme Corp., stated that the patent publications validate the strength of the company's enzyme engineering technology and enhance its position for global partnerships focused on greener pharmaceutical manufacturing. The patented ibuprofen synthesis builds on Quantumzyme's proprietary QZyme Workbench™ platform, which integrates quantum mechanics, molecular modeling, and AI-driven optimization to design next-generation biocatalysts. This technology underpins multiple enzyme systems the company is developing for sustainable, high-efficiency production of active pharmaceutical ingredients and specialty chemicals.

The company's next steps include continuing laboratory optimization and scale-up validation of the enzymatic ibuprofen synthesis process, pursuing discussions with global pharmaceutical and contract manufacturing organizations regarding licensing or joint-development frameworks, and filing additional patent applications covering related enzymatic transformations and process improvements. For more information, visit https://www.quantumzymecorp.com and https://www.otcmarkets.com/stock/QTZM.